retatrutide mechanism of action retatrutide clinical trials 2024 2025 The power three: Retatrutide's role in modern obesity and diabetes therapy Retatrutide UK Guide: Key Facts

It is a weekly subcutaneous injection of GIP/GLP-1 receptor agonist

If side effects become limiting, the dose can be reduced or adjustments can be made to meal timing, hydration, or accompanying medications

The excitement of rapid weight loss eventually gives way to the less dramatic work of holding steady

They are usually most severe during titration but tend to improve over 2 to 8 weeks for many people

Check your formulary before signing up

This modification is shared with tirzepatide and other modern incretin analogs, and is essential for achieving the extended duration of action required for once-weekly dosing